Ischemia-modified albümin and malondialdehyde levels in patients with overt and subclinical hyperthyroidism: effects of treatment on oxidative stress

Cihangir Erem; Akile Karacin Suleyman; Nadim Civan; Ahmet Mentese; Irfan Nuhoglu; Aysegul Uzun; Halil Onder Ersoz; Orhan Deger

doi:10.1507/endocrj.EJ14-0542

ORIGINALS

Ischemia-modified albümin and malondialdehyde levels in patients with overt and subclinical hyperthyroidism: effects of treatment on oxidative stress

Cihangir Erem, Akile Karacin Suleyman, Nadim Civan, Ahmet Mentese, Irfan Nuhoglu, Aysegul Uzun, Halil Onder Ersoz, Orhan Deger

Author information

Cihangir Erem
Department of Internal Medicine, Division of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey
Akile Karacin Suleyman
Department of Internal Medicine, Division of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey
Nadim Civan
Department of Internal Medicine, Division of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey
Ahmet Mentese
Department of Clinical Biochemistry, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey
Irfan Nuhoglu
Department of Internal Medicine, Division of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey
Aysegul Uzun
Department of Clinical Biochemistry, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey
Halil Onder Ersoz
Department of Internal Medicine, Division of Endocrinology and Metabolism, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey
Orhan Deger
Department of Clinical Biochemistry, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey

Keywords: Ischemia-modified albumin, Malondialdehyde, Oxidative stress, Biomarker, Overt and subclinical hyperthyroidism

JOURNAL FREE ACCESS

2015 Volume 62 Issue 6 Pages 493-501

DOI https://doi.org/10.1507/endocrj.EJ14-0542

Browse “Advance online publication” version

Details

Abstract

The main purpose of this study was to evaluate the levels of ischemia-modified albumin (IMA) and malondialdehyde (MDA) in patients with OHyper and SHyper, to assess the effects of antithyroid drug (ATD) therapy on the oxidative stress (OS) parameters. Forty-five untreated patients with overt hyperthyroidism (OHyper), 20 untreated patients with subclinical hyperthyroidism (SHyper) and 30 age-and sex-matched healthy controls were prospectively included in the study. Biochemical and hormonal parameters were evaluated in all patients before and after treatment. Compared with the control subjects, the levels of MDA, glucose and TG were significantly increased in patients with SHyper (p<0.05), whereas LDL-C levels were significantly decreased (p<0.01). Patients with OHyper showed significantly elevated MDA and glucose levels (p<0.001) and significantly decreased LDL-C and HDL-C levels compared with the controls (p<0.01). In patients with Graves’ disease, serum TSH levels were inversely correlated with plasma MDA levels (r: -0.42, p<0.05). Plasma MDA levels significantly decreased and levels of TC, LDL-C and HDL-C significantly increased in the groups of OHyper and SHyper after treatment. Serum IMA levels did not significantly change at baseline and with the therapy in all subjects. In conclusion, increased MDA levels in both patient groups represent increased lipid peroxidation which might play an important role in the pathogenesis of the atherosclerosis in these patients. Increased oxidative stress in patients with SHyper and OHyper could be improved by ATD therapy. Also, MDA can be used as a reliable marker of OS and oxidative damage, while IMA is considered to be inappropriate.

Corresponding author

Register with J-STAGE for free!